Fruquintinib Application Scope

ELUNATE® is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, including those who have received prior anti-VEGF therapy and/or anti-EGFR therapy (RAS wild-type) .

Fruquintinib Characteristics

Ingredients: Each capsule contains fruquintinib as the active ingredient.
Properties: Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, designed to inhibit tumor angiogenesis with improved kinase selectivity to minimize off-target toxicities .
Specification: Available in 1 mg and 5 mg oral capsules.
Packaging Specification: Specific packaging details are not provided in the available sources.
Storage: Store at 20°C to 25°C (68°F to 77°F).
Expiry Date: Refer to the packaging for the expiration date.
Executive Standard: Not specified in the provided sources.
Approval Number: Approved by the China National Medical Products Administration (NMPA) in September 2018 .
Date of Revision: Not specified in the provided sources.
Manufacturer: HUTCHMED and Eli Lilly and Company co-market ELUNATE® in China

Guidelines for the Use of Fruquintinib

Dosage and Administration: The recommended dosage is 5 mg orally once daily on days 1 through 21 of each 28-day cycle. Fruquintinib can be taken with or without food. No dose adjustments are recommended for mild to moderate renal or hepatic impairment.
Adverse Reactions: Common adverse reactions include hypertension, hand-foot skin reaction (palmar-plantar erythrodysesthesia), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.
Contraindications: There are no known contraindications.
Precautions:
- Hypertension: Monitor blood pressure prior to and during treatment. Do not initiate treatment unless blood pressure is adequately controlled.
- Hepatotoxicity: Monitor liver function tests before initiation and periodically during treatment.
- Proteinuria: Monitor for proteinuria before and during treatment.
- Impaired Wound Healing: Do not administer for at least 2 weeks before or after major surgery.
- Embryo-Fetal Toxicity: Fruquintinib can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose.

Interactions

Drug Interactions:
- Fruquintinib is metabolized primarily by CYP3A4.
- Avoid concomitant use with strong CYP3A inducers (e.g., rifampin) as they may decrease fruquintinib plasma concentrations, potentially reducing efficacy.
- If possible, avoid concomitant use with moderate CYP3A inducers (e.g., efavirenz). If unavoidable, continue fruquintinib at the recommended dosage.
- No clinically significant interactions observed with strong CYP3A inhibitors (e.g., itraconazole), proton pump inhibitors (e.g., rabeprazole), or P-glycoprotein substrates (e.g., dabigatran etexilate).

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.